

OSIS Workshop: CDER Bioavailability/Bioequivalence Study Sites and Inspections of Good Laboratory Practice

June 13, 2024, 8:50 – 11:25 am EDT

Welcome	8:50 - 9:00 am
Nora Lim, PharmD, BCPS <i>Lieutenant Commander</i> United States Public Health Service <i>Pharmacist</i> Small Business and Industry Assistance (SBIA) Division of Drug Information (DDI) Office of Communications (OCOMM) Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA)	
OSIS 101	9:00 - 9:15 am
Tahseen Mirza, PhD <i>Associate Director for Regulatory Affairs</i> Office of Study Integrity and Surveillance (OSIS) Office of Translational Sciences (OTS) CDER FDA	
Collaboration, Risk Evaluation, and Surveillance Program (CREST)	9:15 - 9:25 am
Clint Mitchell, PhD <i>Lead Pharmacokineticist</i> OSIS OTS CDER FDA	
Gabriel Davila, DVM Biologist OSIS OTS CDER FDA	
BA/BE Analytical Program	9:24 - 9:45 am
Li-Hong (Paul) Ye, PhD <i>Interdisciplinary Scientist</i> Division of New Drug Study Integrity (DNDSI) OSIS OTS CDER FDA	
Q&A Panel	9:45 - 9:55 am
Tahseen Mirza, Clint Mitchell, Gabriel Davila, Li-Hong (Paul) Ye	
Break	9:55 - 10:10 am
BA/BE Clinical Program	10:10 - 10:30 am
Monica Javidnia, PhD <i>Staff Fellow</i> Division of Generic Drug Study Integrity (DGDSI) OSIS OTS CDER FDA	
GLP Program	10:30 - 10:50 am
Mark Seaton, PhD, DABT <i>Senior Pharmacokineticist</i> DNDSI OSIS OTS CDER FDA	

Q&A Panel

10:50 - 11:00 am

Seongeun (Julia) Cho, Mark Seaton

Discussion Panel

11:00 - 11:25 am

Moderator: **Tahseen Mirza, PhD**

Associate Director for Regulatory Affairs

OSIS | OTS | CDER | FDA

Seongeun (Julia) Cho, PhD

Division Director

DGDSI | OSIS | OTS | CDER | FDA

Kimberley Benson, PhD

Deputy Division Director

DGDSI | OSIS | OTS | CDER | FDA

Arindam Dasgupta, PhD

Deputy Division Director

DNDSI | OSIS | OTS | CDER | FDA

Charles Bonapace, PharmD

Division Director

DNDSI | OSIS | OTS | CDER | FDA